208 related articles for article (PubMed ID: 35269713)
1. Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis.
Morrison G; Buckley J; Ostrow D; Varghese B; Cen SY; Werbin J; Ericson N; Cunha A; Lu YT; George T; Smith J; Quinn D; Duddalwar V; Triche T; Goldkorn A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269713
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients.
Keup C; Suryaprakash V; Storbeck M; Hoffmann O; Kimmig R; Kasimir-Bauer S
Cells; 2021 Jan; 10(2):. PubMed ID: 33494385
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
4. Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2021 Nov; 10(11):. PubMed ID: 34831445
[TBL] [Abstract][Full Text] [Related]
5. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
6. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
Schweizer MT; Gulati R; Beightol M; Konnick EQ; Cheng HH; Klemfuss N; De Sarkar N; Yu EY; Montgomery RB; Nelson PS; Pritchard CC
Prostate; 2019 May; 79(7):701-708. PubMed ID: 30865311
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
8. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
[TBL] [Abstract][Full Text] [Related]
9. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.
Daniel M; Knutson TP; Sperger JM; Li Y; Singh A; Stahlfeld CN; Passow C; Auch B; Lang JM; Dehm SM
Endocr Relat Cancer; 2021 Aug; 28(9):645-655. PubMed ID: 34280123
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer.
de Jong AC; Isebia KT; Ling SW; de Weerd V; Van NM; Kraan J; Martens JWM; Mehra N; Hamberg P; Lolkema MP; de Wit R; van der Veldt AAM; Wilting SM
JCO Precis Oncol; 2023 Sep; 7():e2300156. PubMed ID: 38061007
[TBL] [Abstract][Full Text] [Related]
11. Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.
Fernandez-Garcia D; Nteliopoulos G; Hastings RK; Rushton A; Page K; Allsopp RC; Ambasager B; Gleason K; Guttery DS; Ali S; Charles Coombes R; Shaw JA
Br J Cancer; 2022 Nov; 127(10):1858-1864. PubMed ID: 36088510
[TBL] [Abstract][Full Text] [Related]
12. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.
Trujillo B; Wu A; Wetterskog D; Attard G
Br J Cancer; 2022 Nov; 127(8):1394-1402. PubMed ID: 35715640
[TBL] [Abstract][Full Text] [Related]
13. Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities.
Liebs S; Eder T; Klauschen F; Schütte M; Yaspo ML; Keilholz U; Tinhofer I; Kidess-Sigal E; Braunholz D
Oncogene; 2021 Aug; 40(33):5204-5212. PubMed ID: 34230613
[TBL] [Abstract][Full Text] [Related]
14. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
[TBL] [Abstract][Full Text] [Related]
15. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM
Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023
[TBL] [Abstract][Full Text] [Related]
16. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer.
Keup C; Storbeck M; Hauch S; Hahn P; Sprenger-Haussels M; Tewes M; Mach P; Hoffmann O; Kimmig R; Kasimir-Bauer S
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30781720
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
Salvianti F; Gelmini S; Mancini I; Pazzagli M; Pillozzi S; Giommoni E; Brugia M; Di Costanzo F; Galardi F; De Luca F; Castiglione F; Messerini L; Pinzani P; Antonuzzo L
Br J Cancer; 2021 Jul; 125(1):94-100. PubMed ID: 33953347
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
19. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
20. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]